GW Pharmaceuticals plc (GWPH) began trading on the NASDAQ on 29 April 2013

** daily ** 

** weekly **

GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, is engaged in discovering, developing, and commercializing cannabinoid prescription medicines. The company operates through three segments: Sativex Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company's product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

Address

Porton Down Science Park
SALISBURY, ENG SP4 0JQ
United Kingdom

Website 

http://www.gwpharm.com

Key stats and ratios

		2012
Net profit margin	-	7.52%
Operating margin	-	3.15%
EBITD margin	-	1.17%
Return on average assets	-	6.07%
Return on average equity	-	12.81%
Employees	182